Could CBD oceanic work in the fight versus resistant bacterial pressures? The results from the University of Queensland in Australia suggest that it is possible. However prior to taking a look at the research study in depth, it is useful to understand the development of the relationship between bacteria and prescription antibiotics.

Since the advanced discovery of penicillin by Alexander Fleming in 1928, prescription antibiotics have actually been a vital tool in the fight versus bacteria and infections. And although we still use the exact same proven techniques today, bacteria have actually developed. When exposed to prescription antibiotics, specific bacteria, fungis and parasites are able to adjust and cancel the effectiveness of the drug by establishing resistance.

It’s worth pointing out that antimicrobial resistance was most likely to happen anyhow, as the hereditary code for bacteria modifications with time. Nevertheless, it is believed that the overuse of prescription antibiotics is a crucial aspect that accelerates the development of resistant pressures.

According to the World Health Organization, antimicrobial resistance “is an increasingly severe threat to global public health that needs action in all sectors of federal government and in society.” This has actually led researchers to believe outside the box by trying to recognize compounds that could be useful in the fight versus harmful bacteria. Among these compounds is cannabidiol (CBD), a cannabinoid found in Cannabis sativa.

Scientists are searching for new methods to assault infections and resistant bacteria.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that inner CBD works versus Gram-positive bacteria. Strains of Gram-positive bacteria include Staphylococcus aureus (common in skin infections) and Streptococcus pneumoniae (common in bacterial pneumonia).

Dr. Blaskovich presented his findings at an annual conference of the American Society for Microbiology. In vitro samples of both types of gram-positive bacteria were treated with synthetic CBD. The outcomes led Dr. Blaskovich to the conclusion that CBD operates at levels comparable to those of prescription antibiotics vancomycin and daptomycin. He also discovered that CBD appeared to work against gram-positive pressures of resistant bacteria, which many conventional prescription antibiotics are starting to fail.

” In specific, the activity was chosen versus the resistant pressures of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low propensity to induce resistance and was active versus MRSA biofilms. “

The team also carried out another research study utilizing topical CBD to treat a skin infection in mice. Once again, although the outcomes were positive, CBD did not appear to get rid of the infection, but simply to lower the number of bacterial cells.

Could CBD end up being an antibiotic?

While it is easy to hail this work as a significant development in the antibacterial capabilities of CBD, it is too soon to give up on penicillin.

Although it is believed that the effectiveness of CBD might come from the way it attacks the biofilm surrounding bacterial cells, the authors are still uncertain of the mechanism of action of CBD. They also did not think twice to explain the drawbacks of the research study. Dr. Blaskovich pointed out that since the outcomes remain in the initial phases, it is far prematurely for individuals to begin treating their CBD infections themselves.

The research study was also carried out in vitro (outside the human body), and there is a threat that the outcomes of clinical trials will not be the same. Numerous compounds have actually revealed antibacterial efficacy in petri dishes, but then stopped working at this important phase. It needs to also be pointed out that the two studies were carried out in cooperation with Botanix Pharmaceuticals Ltd, a pharmaceutical company specializing in topical CBD products.

Nevertheless, this research could be a crucial step forward for CBD and the fight versus antimicrobial resistance.

Scroll to top